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OBJECTIVES: We performed a national survey to update hepatocellular carcinoma (HCC) epidemiology in Brazil and
determined the clinical and epidemiological profiles of patients with HCC in different Brazilian regions.
METHODS: Data from 29 centers included 1,405 patients diagnosed with HCC from 2004 to 2009.
RESULTS: The median age was 59 (1–92 years old; 78% male). At diagnosis, females were older than males (median
age: 62 vs. 59 years old respectively; p,0.0001). Ninety-eight percent of the patients had cirrhosis (1279/1308).
Hepatitis C virus was the main etiology (54%), followed by hepatitis B virus (16%) and alcohol (14%). In
Southeastern and Southern Brazil, hepatitis C virus accounted for over 55% of cases. In the Northeast and North,
hepatitis C virus accounted for less than 50%, and hepatitis B virus accounted for 22–25% of cases; hepatitis B was
more prevalent in the Northern than in the Southern regions. Some 43%, 35%, and 22% of patients were in early,
intermediate, and advanced stages respectively. Initial therapies for HCC included chemoembolization or
embolization (36%), percutaneous ablation (13%), liver resection (7%), and sorafenib (1%). Liver transplantation
was performed in 242 patients (19%), but it was the initial therapy for only 56 patients (4%).
CONCLUSION: The epidemiology, classification, and therapy selection for HCC varied among Brazilian regions.
Hepatitis C infection was the most common etiology of liver cirrhosis; chemoembolization was the most common
therapy employed. Liver cirrhosis was the main risk factor for HCC development in Brazil.
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INTRODUCTION
Hepatocellular carcinoma (HCC) is one of the most
common cancers in the world. It is responsible for more
than 500,000 deaths/year.1 Liver cirrhosis is the major risk
factor for HCC development.2 The HCC incidence is widely
variable, depending on geographic region and exposure to
secondary risk factors. In some regions of Asia and Africa,
HCC is the major cause of death among cancers. Regions
with the greatest incidence are those highly endemic for
hepatitis B virus (HBV), including Sub-Saharan Africa and
Southeast Asia. Among developed countries, the incidence
of HCC is high in Japan and low in North America.3
In the last decade, the incidence of HCC appears to have
changed in several countries. A rising incidence was
observed in regions of low prevalence; for instance, in the
USA.4 This change was probably associated with the rise in
hepatitis C virus (HCV) as a cause of liver cirrhosis in these
regions. Few data are available regarding the epidemiology
of HCC in areas of low endemism. According to epidemio-
logic and retrospective studies, Brazil was previously
considered to have a low prevalence of HCC.3 In 1997, a
Brazilian survey of HCC showed that HBV was the most
common cause of liver disease in patients with HCC.5 In this
study, we performed a national survey in order to update
HCC epidemiology in Brazil. The objective of this study was
to determine the clinical and epidemiological profiles of
patients with HCC in different Brazilian regions.
METHODS AND MATERIALS
In 2009, we invited members of the Brazilian Society of
Hepatology (Sociedade Brasileira de Hepatologia/SBH) to
complete a survey regarding patients with HCC diagnosed
from January 2004 to October 2009. The questionnaire
collected clinical and epidemiology data, including gender,
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age at HCC diagnosis, presence of cirrhosis, etiology of liver
disease, and the Child–Pugh score. We also collected data
on the HCC type and treatment, including the tumor
characteristics (number, diameter of nodules, and presence
of vascular invasion), the alpha-fetoprotein (AFP) level, and
the type of HCC therapy. This study was approved by the
University of Sao Paulo School of Medicine Ethics
Committee, and it was conducted in accordance with the
ethical principles described by the Declaration of Helsinki.
Physicians from 29 centers (19 in Southeast, 3 in Southern,
3 in Northeast, and 4 in Northern Brazil) completed the
form, which provided data from 1,450 patients. Inclusion
criteria were: HCC diagnosed according to the American
Association for the Study of Liver Diseases (2005) criteria6
and HCC diagnosed between 2004 and 2009. Forty-five
patients were excluded; one because HCC diagnosis could
not be confirmed, and 44 because HCC was diagnosed prior
to 2004. The remaining patients were categorized according
to liver disease etiology, as follows: (1) HCV; (2) HBV; (3)
HCV plus alcohol; (4) HBV plus alcohol; (5) HCV plus HBV;
(6) HBV plus hepatitis Delta virus; (7) alcohol; (8) nonalco-
holic fatty liver disease; (9) hemochromatosis; (10) crypto-
genic; (11) other; and (12) non-cirrhotic.
The patients were also classified into three groups
according to tumor characteristics (size, number, and
presence of vascular invasion), as follows,: (1) early stage
– one nodule with a diameter less than 50 mm or three
nodules with diameters less than 30 mm and absence of
vascular invasion; (2) intermediate stage – any nodule with
a diameter larger than 50 mm or over three nodules and
absence of vascular invasion; (3) advanced stage – presence
of vascular invasion and/or extrahepatic metastasis.
Patients were also classified by the type of therapy used
in the initial HCC treatment, as follows: (1) liver resection;
(2) liver transplantation; (3) percutaneous ablation, includ-
ing ethanol injection, or radiofrequency ablation; (4)
transarterial therapies, including chemoembolization or
embolization; (5) sorafenib; (6) other; and (7) none.
Different Brazilian geographic regions (Southern,
Southeast, Northeast, Northern, and Mid-Western) were
compared in terms of the etiology, HCC classification, and
initial therapy. The Wilcoxon test was used to compare
differences between age and sex. Continuous variables, such
as the AFP level and tumor diameter, were divided into
categories, and differences were compared using the Chi
square test. A p value ,0.05 was considered statistically
significant.
RESULTS
The study population included 1,405 patients: 1,089 males
(78%) and 314 females (22%). The median age was 59 years
old (range: 1–92 years) for the entire population. On
average, females were older than men at HCC diagnosis
(62 vs. 59 years old), and this difference was statistically
significant (p,0.0001). Cirrhosis was present in 98% of cases
(1,279/1,308). The patients included in the study were from
the Southeast region (77%), the Southern region (12%), the
Northeast region (6%), the Northern region (4%), and the
Mid-Western region (1%).
HCC etiology
Hepatitis C virus was present in 716 patients (54%), and
200 of these were associated with alcohol. Hepatitis B virus
was present in 206 patients (16%), and 47 of these were
associated with alcohol. In 37 (3%) patients, HBV was
associated with HCV (n = 30) or hepatitis Delta virus (n = 7).
In 184 patients (14%), alcohol was the only etiology. In 34
patients (3%), the etiology was nonalcoholic fatty liver
disease. In 10 patients (1%), the etiology was hemochroma-
tosis. Cryptogenic cirrhosis was responsible for 41 cases of
HCC (3%). Other causes were present in 51 patients (4%);
these included autoimmune hepatitis, primary biliary
cirrhosis, and fibrolamellar carcinoma. Table 1 shows the
clinical and epidemiological data for 1,405 patients.
In the Southeast and Southern regions, HCV was the main
etiology of liver disease, accounting for more than 55% of
cases. In the Northeast and Northern regions, HCV was the
main etiology, but it was present in less than 50% of cases;
HBV was the next most common etiology, and the
proportion (22–25%) was higher than in the Southern and
Southeast regions. In the Mid-Western region, HBV was the
most common etiology (40%), followed by HCV (30%)
(Figure 1). The difference in liver disease distribution
among different Brazilian regions was statistically signifi-
cant (p,0.0001).
Liver function
Data regarding liver function evaluations were available
for 1,206 patients. Patients were classified as Child–Pugh A
(n = 642, 53%), Child–Pugh B (n = 404, 34%), and Child–
Pugh C (n = 160, 13%). Data regarding the presence of portal
hypertension were available for 542 patients, and it was
present in 77% of those cases.
HCC diagnosis
Data on the HCC diagnosis were available for 1,229
patients. Most patients (n = 779, 63%) were diagnosed based
on imaging examinations. In 556 patients, only one imaging
examination was necessary, either computed tomography or
magnetic resonance imaging. In 223 patients, two imaging
examinations were necessary. In 273 cases (22%), HCC was
diagnosed based on the elevation of AFP (.200 ng/mL)
associated with a liver mass in one imaging examination. In
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177 patients (15%), histology was performed on biopsies;
this included 21 cases that were diagnosed incidentally
based on lesions in the explanted liver.
Tumor characteristics
The number of HCC nodules was evaluated in 1,227
patients. One nodule was found in 651 patients (53%), two
nodules in 201 (16%), three nodules in 96 (8%), and more
than three nodules in 279 (23%) patients. The median tumor
diameter was 40 mm (SD¡34 mm). Macrovascular invasion
was present in 231/1,090 (21%) patients. Most patients
(n = 658/1,157) had AFP levels below 100 ng/mL. The AFP
level was associated with tumor size (p,0.0001). The AFP
was #100 ng/mL in 70% of patients with an HCC tumor
smaller than 30 mm. On the other hand, the AFP was
.100 ng/mL in over 60% of patients with an HCC tumor
.50 mm.
According to the tumor characteristics (size, number of
nodules, and vascular invasion), HCC classification was
possible in 1,056 patients. Classifications of early, inter-
mediate, and advanced stages were made in 43%, 35%, and
22% of patients respectively. In all regions, the majority of
HCC cases were in the early stage (40–55%). In the
Southeast and Southern regions, intermediate HCC cases
were more common than advanced cases, but in the
Northern region, advanced cases were more frequently
diagnosed than intermediate cases. There was a statistically
significant difference in the distribution of tumor staging
between different geographic regions (p= 0.003) (Figure 2).
HCC treatment
The transarterial procedures, chemoembolization and
embolization, were the most common type of initial HCC
therapy (n = 456, 36%); percutaneous ablations, including
ethanol injection and radiofrequency ablation, were per-
formed in 165 patients (13%); liver resection was the
preferred therapy in 87 patients (7%); sorafenib was
prescribed for 17 patients (1%); liver transplantation was
performed in 242 patients (19%), but it was the initial
therapy in only 56 patients (4%). Figure 3 shows the
distribution of patients according to the initial HCC therapy
and Brazilian region.
Figure 4 shows the distribution of patients according to
HCC classification and therapy. Patients in the early stage of
HCC predominated in the group that received potentially
curative therapies, such as liver resection, liver transplant,
and percutaneous ablation. However, an important propor-
tion of patients classified in the intermediate stage (n = 25,
Figure 1 - Distribution of patients according to HCC etiology and Brazilian region.
Figure 2 - Distribution of patients according to HCC classification and Brazilian region.
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33%) received liver resections. Of the 481 (37%) patients
who did not receive any therapy, most had an advanced
tumor and/or Child–Pugh C-grade cirrhosis (55%). Some
patients were awaiting HCC therapy when the question-
naire was completed.
DISCUSSION
This study presented the largest series of patients with
HCC studied in Brazil to date. Compared with a national
survey published in 1997,5 this survey indicated a greater
proportion of patients with liver cirrhosis and that HCV was
the main etiology. We also found differences in the
prevalence of HCC etiologies and in HCC classifications
among different geographic regions. In the Southern and
Southeast regions, HCV and HBV were responsible for
nearly 60% and less than 20% of HCC cases respectively. In
the Northern and Northeast regions, HCV and HBV were
responsible for less than 50% and more than 20% of HCC in
cases respectively. In the Mid-Western region, only 10 cases
were included, but HBV was the main cause of HCC. This
different distribution of HCC etiology probably reflected the
differences in HBV prevalence in Brazil. Previous studies
found that the Northern and Mid-Western regions had the
highest prevalence of the HBV surface antigen in Brazil.7,8
This study was not designed to evaluate the change in
HCC incidence in Brazil. However, in several countries, a
rising incidence of HCC has been related to an increasing
prevalence of HCV infection.9,10 As in other studies
conducted in countries with a low prevalence of HCC, our
study confirmed that HCV infection was more frequently
involved in HCC etiology than HBV infection.11,12 Apart
from HCV, other factors may be associated with an
increased prevalence of HCC in these areas of low
Figure 3 - Distribution of patients according to initial HCC therapy and Brazilian region.
Figure 4 - Distribution of patients according to initial HCC therapy and classification.
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prevalence; for example, an increase in the incidence of risk
factors for nonalcoholic fatty liver disease.13 Currently, HCC
is the main cause of death among patients with compen-
sated cirrhosis.14 This fact may be associated with the
widespread use of screening programs for early detection of
HCC in patients with cirrhosis and better management of
other cirrhotic complications.
In this study, liver cirrhosis was present in 98% of cases.
In the last national survey, liver cirrhosis was present in 71%
of cases.5 The majority of the questionnaire respondents in
this study were hepatologists; this may explain the high
proportion of liver cirrhosis observed in the HCC patients in
this cohort. However, it does not explain the increase in
liver cirrhosis compared with the 1997 survey.5
We observed a very important modification regarding the
HCC diagnosis. In 1997, most patients were diagnosed with
HCC based on histology (91%).5 In the present study, most
patients (63%) were diagnosed with HCC based on imaging
examinations; only 15% underwent a liver biopsy to confirm
the HCC diagnosis. In 2005, the American Association for
the Study of Liver Diseases updated a guideline published
in 2000 by the European Association for the Study of Liver
Diseases regarding the diagnosis and therapy of HCC.6 In
the new guideline, a diagnosis of HCC could be confirmed
with the presence of a focal hepatic lesion with typical
vascularization in a patient with cirrhosis (arterial enhance-
ment followed by washout in late phase) in one imaging
examination for nodules .20 mm, or two imaging examina-
tions for nodules ,20 mm. We can assume that most of the
questionnaire respondents in this study were aware of the
non-invasive method for diagnosing HCC and attempted to
follow international guidelines.
In patients with liver cirrhosis, surveillance with abdom-
inal ultrasound is recommended for an early diagnosis of
HCC.6 Our data supported the notion that AFP should not
be used as a screening tool;15 most patients in the early stage
of HCC had AFP levels#100 ng/mL. Unfortunately, we did
not have the data to distinguish whether patients were
following a regular surveillance program. Despite efforts to
diagnose HCC early, only 43% of our cases were diagnosed
in the early stage. Currently, a large number of patients are
not diagnosed until the advanced stages. We found
significant differences in the distribution of HCC stages
among the different Brazilian regions. The Southern and
Southeast regions showed a high prevalence of intermediate
HCC; in the Mid-Western region, half the patients were in
the early stage, but this should be interpreted with caution
on account of the small number of patients included from
that region. In the Northern region, nearly half the cases
were in the advanced stage. In those patients, HCC therapy
was very limited; our data indicated that over half of the
patients in the advanced stage received no therapy because
of tumor aggressiveness or cirrhosis.
We also found significant differences in the types of HCC
therapy in different Brazilian regions. In the Southern
region, percutaneous ablation for early HCC was performed
more frequently than in other regions. In the Mid-Western
region, the small number of cases did not allow a
determination of the most frequent type of therapy.
Chemoembolization predominated in all regions, and was
the major type of treatment in the early and intermediate
stages. This probably reflected the greater accessibility of
transarterial therapy in all Brazilian regions. Also, our data
showed that the selection of patients for liver resection was
not very restrictive. Nearly half of the cases that under-
went liver resection were not classified in the early stage.
These data indicated that the recommendation guide-
lines for HCC therapy6 are not strictly followed in many
centers.
Liver transplants were performed in 242 patients, but it
was the initial therapy in only 56 of these patients. Most
patients who underwent a liver transplant were given a
bridge therapy to slow tumor progression. Although there is
currently no consensus regarding the best therapy,6 most
patients were treated with chemoembolization. In 2006, the
policy for cadaveric liver distributions was modified, and
liver transplantation became a more accessible therapy
option for patients with HCC in the early stages. No data are
available regarding the number of Brazilian patients who
dropped off the liver transplant list, but the proportion of
HCC patients that received transplants increased. Future
studies must be performed to evaluate the efficacy of HCC
therapies in Brazil.
One of the main limitations of this retrospective study
was the fact that many of the forms were incomplete, and it
did not include all the consecutive cases of HCC that were
treated during the study period at each center. Furthermore,
questions regarding survival and more information on liver
transplants were on the questionnaire, but those questions
were not properly completed. A prospective study should
be performed to evaluate the impact of HCC treatment on
patient survival.
CONCLUSIONS
Liver cirrhosis was the main risk factor for the develop-
ment of HCC in Brazil. HCC epidemiology, classification,
and therapy selection varied among different Brazilian
regions. HCV infection was the most common etiology of
liver cirrhosis in patients with HCC. Efforts to increase
surveillance programs in patients at risk for HCC develop-
ment should be stimulated, because they are cost-effective
in patients suitable for curative therapy. National efforts
to stimulate organ donation should be encouraged to
increase the number of liver transplantations. However,
there remain some discrepancies in treatment indications.
Chemoembolization was the most common therapy used for
patients with HCC, including those in the early stages. Liver
resection was sometimes indicated in patients with a high
risk of recurrence. The majority of patients with advanced
HCC did not have access to new molecular target therapies,
such as sorafenib. Further studies must be performed to
evaluate the impact of HCC treatment in Brazil.
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